Uveitis, Posterior Clinical Trial
Official title:
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis
Verified date | January 2018 |
Source | Can-Fite BioPharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 2019 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female, 18 years of age and over; 2. Diagnosis of active, sight-threatening, noninfectious intermediate or posterior uveitis, as determined by the Standardization of Uveitis Nomenclature (SUN) Working Group Criteria. 3. Vitreous haze in at least 1 eye (the "study eye") of =Grade 3 on the "Miami Scale" at the Screening Visit, as confirmed by the Uveitis Photograph Reading Center; , 4. Best corrected visual acuity (BCVA) in the poorer seeing eye of 1.3 logarithm of the minimum angle of resolution (logMAR) or better by Early Treatment Diabetic Retinopathy Study (ETDRS; equivalent to 20/400) at Screening; 5. Requires, in the judgment of the Investigator, systemic therapy to treat uveitis; 6. No plans for elective ocular surgery during the trial duration; 10. Ability to understand and provide written informed consent. Exclusion Criteria: 1. Primary diagnosis of anterior uveitis; 2. Uveitis of infectious etiology; 3. Presence of chorioretinal scars that are highly suspicious for ocular toxoplasmosis; 4. Confirmed or suspected uveitis of traumatic etiology; 5. Clinically suspected or confirmed central nervous system or ocular lymphoma; 6. Presence of any other form of ocular malignancy in the either eye including choroidal melanoma; 7. Corneal or lens opacities or obscured ocular media other than vitreous haze upon enrollment such that reliable clinical evaluations and grading of the posterior segment cannot be performed; 8. Pupillary dilation inadequate for quality fundus photography; 9. Uncontrolled glaucoma or ocular hypertension in either eye, defined as intraocular pressure (IOP) >21 mm Hg while on medical therapy; 10. Chronic hypotony (IOP <6 mm Hg) in either eye; 11. Presence of an ocular implantable steroid-eluting device; 12. Ocular injection of corticosteroid within 3 months prior to Baseline; 13. Use of Retisert within 6 months prior to baseline; 14. Use of the following within 90 days prior to Baseline or anticipated use to either eye during the trial: 1. Intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), or 2. Posterior subtenon steroids; 15. YAG capsulotomy within 30 days prior to Day 1 in the study eye; 16. History of herpetic infection in the study eye or adnexa; 17. Oral corticosteroid dose >20 mg/day prednisone equivalent; 18. Oral corticosteroid dose has been changed within 2 weeks prior to screening, or is expected to change while on study; 19. Systemic immunosuppressive agent dose has been changed within 2 weeks prior to screening; 20. Treatment with systemic monoclonal antibody within the longer of 1 month or 5 serum half-lives, prior to screening; 21. Diagnosis or history of Behçet's Disease; 22. Any significant ocular disease that could compromise vision in either eye, including but not limited to: 1. Diabetic retinopathy: proliferative diabetic retinopathy or non-proliferative diabetic retinopathy that compromise vision, 2. Wet age-related macular degeneration, and 3. Myopic degeneration with active subfoveal choroidal neovascularization. |
Country | Name | City | State |
---|---|---|---|
Israel | Bnei-Zion Medical Center | Haifa |
Lead Sponsor | Collaborator |
---|---|
Can-Fite BioPharma |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity of uveitis on standardized photographic assessment | Standardized fundus photographs will be obtained and uniformly assessed in a masked fashion at the Reading Center | 24 weeks | |
Secondary | Safety of CF101 | Frequency, nature, and severity of adverse events | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00570479 -
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
|
Phase 1 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Terminated |
NCT03656692 -
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
|
Phase 4 | |
Completed |
NCT02255032 -
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
|
Phase 2 | |
Completed |
NCT00035906 -
Research Study in Patients With Persistent Macular Edema
|
Phase 2 | |
Recruiting |
NCT05101928 -
Ozurdex Monotherapy Trial
|
Phase 4 | |
Terminated |
NCT05070728 -
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
|
Phase 3 | |
Completed |
NCT02595398 -
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
|
Phase 3 | |
Recruiting |
NCT03066869 -
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
|
Phase 4 | |
Completed |
NCT01539577 -
A Long-Term Safety Study of OZURDEX® in Clinical Practice
|
N/A | |
Recruiting |
NCT05322070 -
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
|
Phase 4 | |
Recruiting |
NCT06085079 -
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
|
Phase 4 | |
Completed |
NCT03145025 -
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
|
||
Completed |
NCT03598452 -
High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients
|
N/A | |
Completed |
NCT02049476 -
Study of the Effectiveness of Ozurdex for the Control of Uveitis
|
Phase 4 | |
Completed |
NCT00404612 -
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT00404742 -
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT02952001 -
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
|
||
Not yet recruiting |
NCT06431373 -
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
|
Phase 3 | |
Completed |
NCT03097315 -
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
|
Phase 3 |